Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LSS | P48449 | 7/20 | 0.52 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449531 | 0.97 | LSS (0.56) | MEN1KMT2ALSSTRPV4GAA | |
| SCHEMBL6447839 | 0.84 | TRPV4 (0.46) | MEN1KMT2ALSSTRPV4GAA | |
| SCHEMBL6446550 | 0.82 | TRPV4 (0.48) | MEN1KMT2ATRPV4GAAALDH1A1 | |
| SCHEMBL6450324 | 0.81 | LSS (0.64) | MEN1KMT2ALSSTRPV4GAA | |
| SCHEMBL6450254 | 0.81 | TRPV4 (0.51) | MEN1KMT2ATRPV4GAAALDH1A1 | |
| SCHEMBL4807767 | 0.79 | LSS (0.80) | LSSHTR2AHTR2C | |
| SCHEMBL4807775 | 0.79 | LSS (0.80) | LSSHTR2AHTR2C | |
| SCHEMBL6448201 | 0.78 | LSS (0.69) | MEN1KMT2ALSSTRPV4GAA | |
| SCHEMBL27519978 | 0.78 | MEN1 (0.60) | MEN1KMT2ATRPV4GAAALDH1A1 | |
| SCHEMBL17551672 | 0.75 | MEN1 (0.60) | MEN1KMT2ATRPV4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1317432-A1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | MEN1 1040/4885KMT2A 3743/4885LSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.